NEW YORK (GenomeWeb News) – Hybrigenics said today that it has signed a co-marketing agreement with Dualsystems Biotech covering yeast two-hybrid screening services for full membrane proteins.
 
Under the terms of the agreement, both Dualsystems and Hybrigenics will commercialize Dualsystems’ DUALmembrane screens, which were designed for identifying protein interactions involving full membrane proteins.
 
Hybrigenics will perform the screens on its ISO 9001-certified yeast two-hybrid platform.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.